Background. In Vietnam, there has been an increase in efforts to monitor and prevent mother-to-child transmission of HIV since 2013. However, data on HIV drug resistance among HIV-1 infected children younger than 18 months of age remain limited. The study fills a critical knowledge gap by providing important insights into the prevalence of resistance among this population in the Southern and Central Highland provinces of Vietnam.Objective. This study aimed to determine the prevalence of HIV drug resistance and patterns of mutation among treatment-naïve children under the age of 18 months who had been recently diagnosed with HIV.Material and methods. Between May 2017 and May 2021, stored remnant DBS samples were collected from children under the age of 18 months who had been diagnosed with HIV through routine Early Infant Diagnosis testing in Central Highland and Southern Vietnam. HIV drug resistance tests were performed, and interpretation was done using the Stanford algorithm.Results and discussion. Overall, 111 samples with eligible viremia for sequencing (ct value <31) were collected for genotyping, in which 110 protease sequences and 106 complete reverse transcriptase regions were generated. Males were 61.3%, 52.3% were aged from 6 weeks to <9 months and 37.0% were breastfed. Access to mother-to-child intervention was reported in 60.3%. The accumulation of major drug resistance mutations was found in 43.8% of infants and most of them were resistant to Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) (37.7%). High-level resistance to Nevirapine was present in 40% of cases. The risk factors associated with NNRTI resistance were antiretroviral prophylaxis (aOR: 3.68, 95% CI: 1.83–7.45) and breast-feeding history (aOR: 2.16, 95% CI: 1.03–4.53). CRF01-AE was the predominant subtype.Conclusion. The study identified a high prevalence of resistance to NNRTIs among HIV-1 infected infants less than 18 months of age in the Southern and Central Highland provinces of Vietnam. This highlights the need for further investigation and a potentially larger national survey to confirm the extent of this issue in Vietnam. Our findings support the current actions of the Vietnam Ministry of Health, which prioritize integrase inhibitor-based regimens as the preferred first line of ART for children to achieve durable viral suppression and minimize treatment failure. This approach aligns with the recommendations of the World Health Organization.
27 February 2025 in Beilstein Journal of Nanotechnology
In this study, berberine nanoparticles (BerNPs) were prepared using a wet-milling method with zirconium balls to enhance bioavailability and expand potential applications. The particle size and physicochemical properties of the BerNPs were analyzed using field-emission scanning electron microscopy (FE-SEM), UV–vis spectroscopy, X-ray diffraction, and Fourier-transform infrared spectroscopy. The broth dilution method was used to determine the antimicrobial activity of the BerNPs against Streptococcus mutans (S. mutans). The impact of the BerNPs on the cell surface of S. mutans was evaluated through FE-SEM analysis, focusing on its ability to inhibit biofilm formation. The results demonstrated that BerNPs were produced with an average particle size of 40–65 nm. The chemical structure of BerNPs remained consistent with that of berberine, with no modifications occurring during nanoparticle preparation. The BerNPs exhibited the ability to inhibit S. mutans, with minimum inhibitory concentration and minimum bactericidal concentration values of 78.1 and 312.5 µg/mL, respectively. BerNPs caused significant damage to S. mutans cells, disrupting the cell membrane structure, and leading to cell lysis and death. Additionally, BerNPs effectively inhibited the biofilm formation of S. mutans. In summary, BerNPs demonstrated a potent inhibitory effect on the activities of S. mutans at selectively applied concentrations.
1 June 2026 in Russian Journal of Infection and Immunity
Background. Southern Vietnam is hyperendemic for Hepatitis B virus (HBV) infection, yet comparative data on the full spectrum of HB serological and molecular profiles — including susceptibility and occult infection — between HIV-infected and healthy adults in this setting remain limited. The aim of this study was to comprehensively evaluate and compare the serological and molecular markers and profiles of Hepatitis B virus infection between HIV-infected patients and apparently healthy adults in Southern Vietnam. Materials and methods. A comparative cross-sectional study was conducted on 713 participants (316 HIV-infected and 397 healthy adults). Blood plasma samples were screened for HBsAg, anti-HBs IgG, and anti-HBc IgG markers. HBV DNA testing was performed using a high-sensitivity in-house PCR. Multivariable logistic regression and interaction analyses were employed for comparative analysis. Results. HBsAg prevalence was comparably high in both the healthy (17.6%) and HIV-infected (16.1%) cohorts, reflecting early-life exposure. However, the HIV cohort exhibited a significantly higher rate of seronegativity for all markers (43.0% vs 16.1%; p 0.001). The burden of OBI was two-fold higher in the HIV group (17.1%) compared to healthy controls (9.3%; aOR = 2.00). Notably, 6.65% of seronegative HIV patients (“triple-negative”) tested positive for HBV DNA, a prevalence 13-fold higher than in controls (0.50%). Age-trend analysis revealed that while healthy adults accumulated immunity with age, HIV-infected individuals exhibited “immune erasure” and seroreversion, leading to the loss of protective antibodies and increased risk of occult infection in older age. Conclusion. Our study documents important differences in HBV serological and molecular profiles between HIV-infected patients and healthy adults in a hyper-endemic setting. Our cross-sectional data are consistent with HIV-associated perturbation of humoral immunity, manifested by higher rates of seronegativity. The detection of triple-negative occult HBV infection highlights a limitation of serology-only screening. In endemic settings, clinicians and public health programs should therefore consider risk-stratified approaches that incorporate molecular testing, particularly for high-risk subgroups where universal screening is not feasible.